Abnormally rapid reversal learning and reduced response to antipsychotic drugs following ovariectomy in female rats

Psychoneuroendocrinology

Volumn 37, Issue 2, 2012, Pages 200-212

  Arad, Michal ^a   Weiner, Ina ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

17 Estradiol; Animal models; Antipsychotic drugs; Ovariectomy; Reversal learning; Schizophrenia; Selective attention

Indexed keywords

CLOZAPINE; ESTRADIOL; HALOPERIDOL;

ABNORMALLY RAPID REVERSAL LEARNING; ANIMAL EXPERIMENT; ARTICLE; ATTENTION DISTURBANCE; CONTROLLED STUDY; DISCRIMINATION REVERSAL; DRUG EFFECT; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; LEARNING DISORDER; LOW DRUG DOSE; MENTAL TASK; MONOTHERAPY; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; SELECTIVE ATTENTION; SHAM PROCEDURE;

ANIMALS; ANTIPSYCHOTIC AGENTS; ATTENTION; CLOZAPINE; DISCRIMINATION LEARNING; ESTRADIOL; ESTROGENS; FEMALE; HALOPERIDOL; MODELS, ANIMAL; OVARIECTOMY; RATS; RATS, WISTAR; REVERSAL LEARNING; SCHIZOPHRENIA;

EID: 83555174395     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2011.06.004     Document Type: Article

References (150)

1. Akhondzadeh S., Nejatisafa A.A., Amini H., Mohammadi M.R., Larijani B., Kashani L., Raisi F., Kamalipour A. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1007-1012.
2. Anscombe R. The disorder of consciousness in schizophrenia. Schizophr. Bull. 1987, 13:241-260.
3. Arad M., Weiner I. Fluctuation of latent inhibition along the estrous cycle in the rat: modeling the cyclicity of symptoms in schizophrenic women?. Psychoneuroendocrinology 2008, 33:1401-1410.
4. Arad M., Weiner I. Disruption of latent inhibition induced by ovariectomy can be reversed by estradiol and clozapine as well as by co-administration of haloperidol with estradiol but not by haloperidol alone. Psychopharmacology (Berl) 2009, 206:731-740.
5. Arad M., Weiner I. Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis?. Neuropsychopharmacology 2010, 35:1570-1582.
6. Arad M., Weiner I. Sex-dependent antipsychotic capacity of 17beta-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males. Neuropsychopharmacology 2010, 35:2179-2192.
7. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998, 18:63-101.
8. Arvin M., Fedorkova L., Disshon K.A., Dluzen D.E., Leipheimer R.E. Estrogen modulates responses of striatal dopamine neurons to MPP(+): evaluations using in vitro and in vivo techniques. Brain Res. 2000, 872:160-171.
9. Assie M.B., Consul-Denjean N., Koek W., Newman-Tancredi A. Differential in vivo inhibition of [3H]nemonapride binding by atypical antipsychotics in rat striatum, olfactory lobes, and frontal cortex. Pharmacology 2005, 75:63-68.
10. Assie M.B., Dominguez H., Consul-Denjean N., Newman-Tancredi A. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. Naunyn. Schmiedebergs Arch. Pharmacol. 2006, 373:441-450.
11. Baruch I., Hemsley D.R., Gray J.A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J. Nerv. Ment. Dis. 1988, 176:598-606.
12. Bazzett T.J., Becker J.B. Sex differences in the rapid and acute effects of estrogen on striatal D2 dopamine receptor binding. Brain Res. 1994, 637:163-172.
13. Becker J.B. Estrogen rapidly potentiates amphetamine-induced striatal dopamine release and rotational behavior during microdialysis. Neurosci. Lett. 1990, 118:169-171.
14. Becker J.B., Beer M.E. The influence of estrogen on nigrostriatal dopamine activity: behavioral and neurochemical evidence for both pre- and postsynaptic components. Behav. Brain Res. 1986, 19:27-33.
15. Becker J.B., Rudick C.N. Rapid effects of estrogen or progesterone on the amphetamine-induced increase in striatal dopamine are enhanced by estrogen priming: a microdialysis study. Pharmacol. Biochem. Behav. 1999, 64:53-57.
16. Becker J.B., Snyder P.J., Miller M.M., Westgate S.A., Jenuwine M.J. The influence of estrous cycle and intrastriatal estradiol on sensorimotor performance in the female rat. Pharmacol. Biochem. Behav. 1987, 27:53-59.
17. Bedard P., Boucher R., Di Paolo T., Labrie F. Biphasic effect of estradiol and domperidone on lingual dyskinesia in monkeys. Exp. Neurol. 1983, 82:172-182.
18. Bedard P., Dankova J., Boucher R., Langelier P. Effect of estrogens on apomorphine-induced circling behavior in the rat. Can. J. Physiol. Pharmacol. 1978, 56:538-541.
19. Bedard P.J., Malouin F., Dipaolo T., Labrie F. Estradiol, TRH and striatal dopaminergic mechanisms. Prog. Neuropsychopharmacol. Biol. Psychiatry 1982, 6:555-561.
20. Bohacek J., Daniel J.M. The beneficial effects of estradiol on attentional processes are dependent on timing of treatment initiation following ovariectomy in middle-aged rats. Psychoneuroendocrinology 2010, 35:694-705.
21. Bosse R., Di Paolo T. Dopamine and GABAA receptor imbalance after ovariectomy in rats: model of menopause. J. Psychiatry Neurosci. 1995, 20:364-371.
22. Castner S.A., Becker J.B. Sex differences in the effect of amphetamine on immediate early gene expression in the rat dorsal striatum. Brain Res. 1996, 712:245-257.
23. Chavez C., Gogos A., Jones M.E., van den Buuse M. Psychotropic drug-induced locomotor hyperactivity and prepulse inhibition regulation in male and female aromatase knockout (ArKO) mice: role of dopamine D1 and D2 receptors and dopamine transporters. Psychopharmacology (Berl) 2009, 206:267-279.
24. Chavez C., Hollaus M., Scarr E., Pavey G., Gogos A., van den Buuse M. The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study. Brain Res. 2010, 1321:51-59.
25. Clarke H.F., Dalley J.W., Crofts H.S., Robbins T.W., Roberts A.C. Cognitive inflexibility after prefrontal serotonin depletion. Science 2004, 304:878-880.
26. Clarke H.F., Hill G.J., Robbins T.W., Roberts A.C. Dopamine, but not serotonin, regulates reversal learning in the marmoset caudate nucleus. J. Neurosci. 2011, 31:4290-4297.
27. Clarke H.F., Walker S.C., Dalley J.W., Robbins T.W., Roberts A.C. Cognitive inflexibility after prefrontal serotonin depletion is behaviorally and neurochemically specific. Cereb. Cortex 2007, 17:18-27.
28. Clatworthy P.L., Lewis S.J., Brichard L., Hong Y.T., Izquierdo D., Clark L., Cools R., Aigbirhio F.I., Baron J.C., Fryer T.D., Robbins T.W. Dopamine release in dissociable striatal subregions predicts the different effects of oral methylphenidate on reversal learning and spatial working memory. J. Neurosci. 2009, 29:4690-4696.
29. Cools R., Frank M.J., Gibbs S.E., Miyakawa A., Jagust W., D'Esposito M. Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration. J. Neurosci. 2009, 29:1538-1543.
30. Cyr M., Bosse R., Di Paolo T. Gonadal hormones modulate 5-hydroxytryptamine2A receptors: emphasis on the rat frontal cortex. Neuroscience 1998, 83:829-836.
31. Cyr M., Calon F., Morissette M., Di Paolo T. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J. Psychiatry Neurosci. 2002, 27:12-27.
32. Dalton G.L., Ma L.M., Phillips A.G., Floresco S.B. Blockade of NMDA GluN2B receptors selectively impairs behavioral flexibility but not initial discrimination learning. Psychopharmacology (Berl) 2011.
33. Daniel J.M. Effects of oestrogen on cognition: what have we learned from basic research?. J. Neuroendocrinol. 2006, 18:787-795.
34. De Ryck M., Hruska R.E., Silbergeld E.K. Estrogen and haloperidol-induced versus handling-related catalepsy in male rats. Pharmacol. Biochem. Behav. 1982, 17:1027-1035.
35. Di Paolo T., Bedard P.J., Dupont A., Poyet P., Labrie F. Effects of estradiol on intact and denervated striatal dopamine receptors and on dopamine levels: a biochemical and behavioral study. Can. J. Physiol. Pharmacol. 1982, 60:350-357.
36. Di Paolo T., Carmichael R., Labrie F., Raynaud J.P. Effects of estrogens on the characteristics of [3H]spiroperidol and [3H]RU24213 binding in rat anterior pituitary gland and brain. Mol. Cell. Endocrinol. 1979, 16:99-112.
37. Di Paolo T., Daigle M., Labrie F. Effect of estradiol and haloperidol on hypophysectomized rat brain dopamine receptors. Psychoneuroendocrinology 1984, 9:399-404.
38. Di Paolo T., Dupont A., Daigle M. Effect of chronic estradiol treatment on dopamine concentrations in discrete brain nuclei of hypophysectomized female rats. Neurosci. Lett. 1982, 32:295-300.
39. Disshon K.A., Boja J.W., Dluzen D.E. Inhibition of striatal dopamine transporter activity by 17beta-estradiol. Eur. J. Pharmacol. 1998, 345:207-211.
40. Disshon K.A., Dluzen D.E. Estrogen as a neuromodulator of MPTP-induced neurotoxicity: effects upon striatal dopamine release. Brain Res. 1997, 764:9-16.
41. Dodds C.M., Muller U., Clark L., van Loon A., Cools R., Robbins T.W. Methylphenidate has differential effects on blood oxygenation level-dependent signal related to cognitive subprocesses of reversal learning. J. Neurosci. 2008, 28:5976-5982.
42. Donner N., Handa R.J. Estrogen receptor beta regulates the expression of tryptophan-hydroxylase 2 mRNA within serotonergic neurons of the rat dorsal raphe nuclei. Neuroscience 2009, 163:705-718.
43. Dopson J.C., Esber G.R., Pearce J.M. Differences in the associability of relevant and irrelevant stimuli. J. Exp. Psychol. Anim. Behav. Process. 2010, 36:258-267.
44. Fink G., Sumner B.E., McQueen J.K., Wilson H., Rosie R. Sex steroid control of mood, mental state and memory. Clin. Exp. Pharmacol. Physiol. 1998, 25:764-775.
45. Frick K.M. Estrogens and age-related memory decline in rodents: what have we learned and where do we go from here?. Horm. Behav. 2009, 55:2-23.
46. Gelissen M., Cools A. Effect of intracaudate haloperidol and apomorphine on switching motor patterns upon current behaviour of cats. Behav. Brain Res. 1988, 29:17-26.
47. Gibbs R.B. Estrogen therapy and cognition: a review of the cholinergic hypothesis. Endocr. Rev. 2010, 31:224-253.
48. Gogos A., Kwek P., Chavez C., van den Buuse M. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors. J. Pharmacol. Exp. Ther. 2010, 333:218-227.
49. Gosselin G., Oberling P., Di Scala G. Antagonism of amphetamine-induced disruption of latent inhibition by the atypical antipsychotic olanzapine in rats. Behav. Pharmacol. 1996, 7:820-826.
50. Gray J.A., Feldon J., Rawlins J.N.P., Hemsley D.R., Smith A.D. The neuropsychology of schizophrenia. Behav. Brain Sci. 1991, 14:1-84.
51. Grayson B., Idris N.F., Neill J.C. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav. Brain Res. 2007, 184:31-38.
52. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003, 28(Suppl. 2):17-54.
53. Hafner H., Behrens S., De Vry J., Gattaz W.F. An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia. Psychiatry Res. 1991, 38:125-134.
54. Hafner H., Riecher A., Maurer K., Loffler W., Munk-Jorgensen P., Stromgren E. How does gender influence age at first hospitalization for schizophrenia? A transnational case register study. Psychol. Med. 1989, 19:903-918.
55. Hajos M. Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Trends Pharmacol. Sci. 2006, 27:391-398.
56. Henderson V.W. Alzheimer's disease and other neurological disorders. Climacteric 2007, 10(Suppl. 2):92-96.
57. Horacek J., Bubenikova-Valesova V., Kopecek M., Palenicek T., Dockery C., Mohr P., Hoschl C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006, 20:389-409.
58. Itagaki S., Yabe H., Mori Y., Ishikawa H., Takanashi Y., Niwa S.I. Event-related potentials in patients with adult attention-deficit/hyperactivity disorder versus schizophrenia. Psychiatry Res. 2011.
59. Jori A., Cecchetti G. Homovanillic acid levels in rat striatum during the oestrous cycle. J. Endocrinol. 1973, 58:341-342.
60. Joseph M.H., Peters S.L., Moran P.M., Grigoryan G.A., Young A.M., Gray J.A. Modulation of latent inhibition in the rat by altered dopamine transmission in the nucleus accumbens at the time of conditioning. Neuroscience 2000, 101:921-930.
61. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 2003, 160:13-23.
62. Kapur S. How antipsychotics become anti-" psychotic" - from dopamine to salience to psychosis. Trends Pharmacol. Sci. 2004, 25:402-406.
63. Kapur S., Mizrahi R., Li M. From dopamine to salience to psychosis - linking biology, pharmacology and phenomenology of psychosis. Schizophr. Res. 2005, 79:59-68.
64. Killcross A.S., Dickinson A., Robbins T.W. Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentional dysfunction. Psychopharmacology (Berl) 1994, 115:185-195.
65. Killcross A.S., Robbins T.W. Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm. Psychopharmacology (Berl) 1993, 110:479-489.
66. Korhonen S., Saarijarvi S., Aito M. Successful estradiol treatment of psychotic symptoms in the premenstrual phase: a case report. Acta Psychiatr. Scand. 1995, 92:237-238.
67. Kulkarni J. Oestrogen - a new treatment approach for schizophrenia?. Med. J. Aust. 2009, 190:S37-S38.
68. Kulkarni J., de Castella A., Fitzgerald P.B., Gurvich C.T., Bailey M., Bartholomeusz C., Burger H. Estrogen in severe mental illness: a potential new treatment approach. Arch. Gen. Psychiatry 2008, 65:955-960.
69. Kulkarni J., de Castella A., Headey B., Marston N., Sinclair K., Lee S., Gurvich C., Fitzgerald P.B., Burger H. Estrogens and men with schizophrenia: is there a case for adjunctive therapy?. Schizophr. Res. 2011, 125:278-283.
70. Kulkarni J., de Castella A., Smith D., Taffe J., Keks N., Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr. Res. 1996, 20:247-252.
71. Kulkarni J., Gurvich C., Gilbert H., Mehmedbegovic F., Mu L., Marston N., Gavrilidis E., de Castella A. Hormone modulation: a novel therapeutic approach for women with severe mental illness. Aust. N. Z. J. Psychiatry 2008, 42:83-88.
72. Kulkarni J., Riedel A., de Castella A.R., Fitzgerald P.B., Rolfe T.J., Taffe J., Burger H. Estrogen - a potential treatment for schizophrenia. Schizophr. Res. 2001, 48:137-144.
73. Landry M., Levesque D., Di Paolo T. Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology 2002, 76:214-222.
74. Lane H.Y., Chang Y.C., Chang W.H., Lin S.K., Tseng Y.T., Jann M.W. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J. Clin. Psychiatry 1999, 60:36-40.
75. Lawrence D.H. Acquired distinctiveness of cues; transfer between discrimination on the basis of familiarity with the stimulus. J. Exp. Psychol. 1949, 39:770-784.
76. Lawrence D.H. Acquired distinctiveness of cues: selective association in a constant stimulus situation. J. Exp. Psychol. 1950, 40:175-188.
77. Le Saux M., Di Paolo T. Influence of oestrogenic compounds on monoamine transporters in rat striatum. J. Neuroendocrinol. 2006, 18:25-32.
78. Lee B., Groman S., London E.D., Jentsch J.D. Dopamine D2/D3 receptors play a specific role in the reversal of a learned visual discrimination in monkeys. Neuropsychopharmacology 2007, 32:2125-2134.
79. Leysen J.E., Janssen P.M., Schotte A., Luyten W.H., Megens A.A. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl) 1993, 112:S40-54.
80. Liu B., Dluzen D.E. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease. Clin. Exp. Pharmacol. Physiol. 2007, 34:555-565.
81. Lubow R.E. Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia. Schizophr. Bull. 2005, 31:139-153.
82. Luck S.J., Gold J.M. The construct of attention in schizophrenia. Biol. Psychiatry 2008, 64:34-39.
83. Lyon M. Animal models of mania and schizophrenia. Behavioral Models in Psychopharmacology: Theoretical, Industrial and Clinical Perspectives 1991, University Press Cambridge. P. Willner (Ed.).
84. Mackintosh N.J. A theory of attention: variations in the associability of stimuli with reinforcement. Psychol. Rev. 1975, 82:276-298.
85. Mackintosh N.J. Conditioning and Associative Learning 1983, Clarendon Press, Oxford.
86. Magaro P.A. Cognition in Schizophrenia and Paranoia: The Integration of Cognitive Processes 1980, Erlbaum, Hillsdale, NJ.
87. Marcondes F.K., Bianchi F.J., Tanno A.P. Determination of the estrous cycle phases of rats: some helpful considerations. Braz. J. Biol. 2002, 62:609-614.
88. McDermott J.L. Effects of estrogen upon dopamine release from the corpus striatum of young and aged female rats. Brain Res. 1993, 606:118-125.
89. Mellios N., Galdzicka M., Ginns E., Baker S.P., Rogaev E., Xu J., Akbarian S. Gender-specific reduction of estrogen-sensitive small RNA, miR-30b, in subjects with schizophrenia. Schizophr. Bull. 2010.
90. Moran P.M., Fischer T.R., Hitchcock J.M., Moser P.C. Effects of clozapine on latent inhibition in the rat. Behav. Pharmacol. 1996, 7:42-48.
91. Morissette M., Al Sweidi S., Callier S., Di Paolo T. Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Mol. Cell. Endocrinol. 2008, 290:60-69.
92. Morissette M., Di Paolo T. Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites. J. Neurochem. 1993, 60:1876-1883.
93. Mortimer A.M. Relationship between estrogen and schizophrenia. Expert Rev. Neurother. 2007, 7:45-55.
94. Moser P.C., Hitchcock J.M., Lister S., Moran P.M. The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res. Brain Res. Rev. 2000, 33:275-307.
95. Nicoletti F., Ferrara N., Patti F., Viglianesi M., Rampello L., Bianchi A., Reggio A., Scapagnini U. Influence of sex steroids and prolactin on haloperidol-induced catalepsy. Brain Res. 1983, 279:352-358.
96. Nuechterlein K.H., Pashler H.E., Subotnik K.L. Translating basic attentional paradigms to schizophrenia research: reconsidering the nature of the deficits. Dev. Psychopathol. 2006, 18:831-851.
97. O'Neill M., Brown V.J. The effect of striatal dopamine depletion and the adenosine A2A antagonist KW-6002 on reversal learning in rats. Neurobiol. Learn. Mem. 2007, 88:75-81.
98. Oades R.D. The role of noradrenaline in tuning and dopamine in switching between signals in the CNS. Neurosci. Biobehav. Rev. 1985, 9:261-282.
99. Osterlund M.K. Underlying mechanisms mediating the antidepressant effects of estrogens. Biochim. Biophys. Acta 2010, 1800:1136-1144.
100. Palermo-Neto J., Dorce V.A. Influences of estrogen and/or progesterone on some dopamine related behavior in rats. Gen. Pharmacol. 1990, 21:83-87.
101. Pearce J.M., Esber G.R., George D.N., Haselgrove M. The nature of discrimination learning in pigeons. Learn. Behav. 2008, 36:188-199.
102. Perlman W.R., Tomaskovic-Crook E., Montague D.M., Webster M.J., Rubinow D.R., Kleinman J.E., Weickert C.S. Alteration in estrogen receptor alpha mRNA levels in frontal cortex and hippocampus of patients with major mental illness. Biol. Psychiatry 2005, 58:812-824.
103. Perlman W.R., Webster M.J., Kleinman J.E., Weickert C.S. Reduced glucocorticoid and estrogen receptor alpha messenger ribonucleic acid levels in the amygdala of patients with major mental illness. Biol. Psychiatry 2004, 56:844-852.
104. Powell C.M., Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?. Biol. Psychiatry 2006, 59:1198-1207.
105. Rascle C., Mazas O., Vaiva G., Tournant M., Raybois O., Goudemand M., Thomas P. Clinical features of latent inhibition in schizophrenia. Schizophr. Res. 2001, 51:149-161.
106. Riecher-Rossler A. Oestrogen effects in schizophrenia and their potential therapeutic implications - review. Arch. Womens Ment. Health 2002, 5:111-118.
107. Riecher-Rossler A., Hafner H. Schizophrenia and oestrogens - is there an association?. Eur. Arch. Psychiatry Clin. Neurosci. 1993, 242:323-328.
108. Riecher-Rossler A., Hafner H., Stumbaum M., Maurer K., Schmidt R. Can estradiol modulate schizophrenic symptomatology?. Schizophr. Bull. 1994, 20:203-214.
109. Ruob C., Elsner J., Weiner I., Feldon J. Amphetamine-induced disruption and haloperidol-induced potentiation of latent inhibition depend on the nature of the stimulus. Behav. Brain Res. 1997, 88:35-41.
110. Russig H., Kovacevic A., Murphy C.A., Feldon J. Haloperidol and clozapine antagonise amphetamine-induced disruption of latent inhibition of conditioned taste aversion. Psychopharmacology (Berl) 2003, 170:263-270.
111. Salokangas R.K. Gender and the use of neuroleptics in schizophrenia. Further testing of the oestrogen hypothesis. Schizophr. Res. 1995, 16:7-16.
112. Saugstad L.F. Social class, marriage, and fertility in schizophrenia. Schizophr. Bull. 1989, 15:9-43.
113. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996, 124:57-73.
114. Seeman M.V. Prenatal gonadal hormones and schizophrenia in men and women. Psychiatr. J. Univ. Ott. 1989, 14:473-475.
115. Seeman M.V., Lang M. The role of estrogens in schizophrenia gender differences. Schizophr. Bull. 1990, 16:185-194.
116. Sherwin B.B., Henry J.F. Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review. Front. Neuroendocrinol. 2008, 29:88-113.
117. Shieh K.R., Yang S.C. Effects of estradiol on the stimulation of dopamine turnover in mesolimbic and nigrostriatal systems by cocaine- and amphetamine-regulated transcript peptide in female rats. Neuroscience 2008, 154:1589-1597.
118. Solomon P.R., Crider A., Winkelman J.W., Turi A., Kamer R.M., Kaplan L.J. Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder. Biol. Psychiatry 1981, 16:519-537.
119. Suda S., Segi-Nishida E., Newton S.S., Duman R.S. A postpartum model in rat: behavioral and gene expression changes induced by ovarian steroid deprivation. Biol. Psychiatry 2008, 64:311-319.
120. Summer B.E., Fink G. Estrogen increases the density of 5-hydroxytryptamine(2A) receptors in cerebral cortex and nucleus accumbens in the female rat. J. Steroid Biochem. Mol. Biol. 1995, 54:15-20.
121. Sumner B.E., Fink G. The density of 5-hydoxytryptamine2A receptors in forebrain is increased at pro-oestrus in intact female rats. Neurosci. Lett. 1997, 234:7-10.
122. Sumner B.E., Fink G. Testosterone as well as estrogen increases serotonin2A receptor mRNA and binding site densities in the male rat brain. Brain Res. Mol. Brain Res. 1998, 59:205-214.
123. Sutcliffe J.S., Rhaman F., Marshall K.M., Neill J.C. Oestradiol attenuates the cognitive deficit induced by acute phencyclidine treatment in mature female hooded-Lister rats. J. Psychopharmacol. 2008, 22:918-922.
124. Sutherland N.S., Mackintosh N.J. Mechanisms of Animal Discrimination Learning 1971, Academic Press, New York.
125. Swerdlow N.R., Koob G.F. Dopamine, schizophrenia, mania and depression: toward a unified hypothesis of cortico-striato-pallido-thalamic function. Behav. Brain Sci. 1987, 10:197-245.
126. Thompson T.L., Moss R.L. Estrogen regulation of dopamine release in the nucleus accumbens: genomic- and nongenomic-mediated effects. J. Neurochem. 1994, 62:1750-1756.
127. Vaillancourt C., Cyr M., Rochford J., Boksa P., Di Paolo T. Effects of ovariectomy and estradiol on acoustic startle responses in rats. Pharmacol. Biochem. Behav. 2002, 74:103-109.
128. van den Bos R., Cools A.R. The involvement of the nucleus accumbens in the ability of rats to switch to cue-directed behaviours. Life Sci. 1989, 44:1697-1704.
129. Van den Buuse M., Eikelis N. Estrogen increases prepulse inhibition of acoustic startle in rats. Eur. J. Pharmacol. 2001, 425:33-41.
130. Wadenberg M.L., Soliman A., VanderSpek S.C., Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001, 25:633-641.
131. Walf A.A., Frye C.A. A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharmacology 2006, 31:1097-1111.
132. Walker S.C., Robbins T.W., Roberts A.C. Differential contributions of dopamine and serotonin to orbitofrontal cortex function in the marmoset. Cereb. Cortex 2009, 19:889-898.
133. Warburton E.C., Joseph M.H., Feldon J., Weiner I., Gray J.A. Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron. Psychopharmacology (Berl) 1994, 114:657-664.
134. Weickert C.S., Miranda-Angulo A.L., Wong J., Perlman W.R., Ward S.E., Radhakrishna V., Straub R.E., Weinberger D.R., Kleinman J.E. Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum. Mol. Genet. 2008, 17:2293-2309.
135. Weiner I. Neural substrates of latent inhibition: the switching model. Psychol. Bull. 1990, 108:442-461.
136. Weiner I. The " two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl) 2003, 169:257-297.
137. Weiner I., Arad M. Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment. Behav. Brain Res. 2009, 204:369-386.
138. Weiner I., Bernasconi E., Broersen L.M., Feldon J. Amphetamine-induced disruption of latent inhibition depends on the nature of the stimulus. Behav. Pharmacol. 1997, 8:442-457.
139. Weiner I., Joel D. Dopamine in schizophrenia: dysfunctional information processing in basal ganglia-thalamocortical split circuits. Handbook of Experimental Pharmacology 2002, 418-472. Springer, Berlin. G. Di Chiara (Ed.).
140. Weiner I., Kidron R., Tarrasch R., Arnt J., Feldon J. The effects of the new antipsychotic, sertindole, on latent inhibition in rats. Behav. Pharmacol. 1994, 5:119-124.
141. Weiner I., Shadach E., Tarrasch R., Kidron R., Feldon J. The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine. Biol. Psychiatry 1996, 40:834-843.
142. Weiner I., Tarrasch R., Bernasconi E., Broersen L.M., Ruttimann T.C., Feldon J. Amphetamine-induced disruption of latent inhibition is not reinforcer-mediated. Pharmacol. Biochem. Behav. 1997, 56:817-826.
143. Wong J., Weickert C.S. Transcriptional interaction of an estrogen receptor splice variant and ErbB4 suggests convergence in gene susceptibility pathways in schizophrenia. J. Biol. Chem. 2009, 284:18824-18832.
144. Wong J., Woon H.G., Weickert C.S. Full length TrkB potentiates estrogen receptor alpha mediated transcription suggesting convergence of susceptibility pathways in schizophrenia. Mol. Cell. Neurosci. 2011, 46:67-78.
145. Xiao L., Becker J.B. Quantitative microdialysis determination of extracellular striatal dopamine concentration in male and female rats: effects of estrous cycle and gonadectomy. Neurosci. Lett. 1994, 180:155-158.
146. Xiao L., Becker J.B. Effects of estrogen agonists on amphetamine-stimulated striatal dopamine release. Synapse 1998, 29:379-391.
147. Xiao L., Jackson L.R., Becker J.B. The effect of estradiol in the striatum is blocked by ICI 182, 780 but not tamoxifen: pharmacological and behavioral evidence. Neuroendocrinology 2003, 77:239-245.
148. Yogev H., Hadar U., Gutman Y., Sirota P. Perseveration and over-switching in schizophrenia. Schizophr. Res. 2003, 61:315-321.
149. Yu P.L., Wu C.I., Lee T.S., Pan W.H., Wang P.S., Wang S.W. Attenuation of estradiol on the reduction of striatal dopamine by amphetamine in ovariectomized rats. J. Cell. Biochem. 2009, 108:1318-1324.
150. Zuckerman L., Weiner I. Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J. Psychiatr. Res. 2005, 39:311-323.